ConductScience.org, home

Paper3317828

Redesigning nature's poisons to create anti-tumor reagents.

Vitetta ES and 4 others. Science, 1987. Cited by 344 papers, by iCite.

Cite this record

ConductScience Library. Redesigning nature's poisons to create anti-tumor reagents. Papers, record 3317828. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/3317828

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Redesigning nature's poisons to create anti-tumor reagents.
PubMed
Journal
Science
PubMed
Year
1987
PubMed
Publication types
Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S., Review
PubMed
Citations, by iCite
344
iCite
Relative citation ratio, by iCite
10.2
iCite
Revised in PubMed
2019-06-18
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Vitetta ESE S
2Fulton RJR J
3May RDR D
4Till MM
5Uhr JWJ W

Source PubMed

Download CSV of authors

Topics7

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
ImmunotoxinsMajor topic
Animals
Antineoplastic Agents
Clinical Trials as Topic
Humans
Neoplasms, Experimental
Recombinant Proteins

Source PubMed

Download CSV of topics

Grants3

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-28149NCI NIH HHSUnited StatesR01CA028149PubMed and NIHNIH RePORTER
CA-41081NCI NIH HHSUnited StatesP01CA041081PubMed and NIHNIH RePORTER
R37CA028149NIHNIH RePORTER

Download CSV of grants

Trials1

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

TrialTitleThe trial lists it asNamed in the paper's record
NCT00001271A Phase I Study of Continuous Infusion Immunotoxin IgG-RFB4-SMPT-dgA in Refractory CD22 Positive B-Cell LymphomaBackground

Source ClinicalTrials.gov

Download CSV of trials

Cited by49

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 344 citations.

PMIDTitleJournalYearIn PapersSource
28451181Decoupling stability and release in disulfide bonds with antibody-small molecule conjugates.Chem Sci2017https://conductscience.org/library/papers/28451181PubMed
19405947Development of a novel small antibody that retains specificity for tumor targeting.J Exp Clin Cancer Res2009https://conductscience.org/library/papers/19405947PubMed
14649886Targeting the over-expressed urokinase-type plasminogen activator receptor on glioblastoma multiforme.J Neurooncol2003https://conductscience.org/library/papers/14649886PubMed
12952291Immunotoxin therapy for CNS tumor.J Neurooncol2003https://conductscience.org/library/papers/12952291PubMed
12070352Design of protein struts for self-assembling nanoconstructs.Proc Natl Acad Sci U S A2002https://conductscience.org/library/papers/12070352PubMed
11773976Gene transfer of interleukin 13 receptor alpha2 chain dramatically enhances the antitumor effect of IL-13 receptor-targeted cytotoxin in human prostate cancer xenografts.Cancer Gene Ther2001https://conductscience.org/library/papers/11773976PubMed
10677537Cure of human carcinoma xenografts by a single dose of pretargeted yttrium-90 with negligible toxicity.Proc Natl Acad Sci U S A2000https://conductscience.org/library/papers/10677537PubMed
8580845Chemically crosslinked protein dimers: stability and denaturation effects.Protein Sci1995https://conductscience.org/library/papers/8580845PubMed
8421689A recombinant immunotoxin that is active on prostate cancer cells and that is composed of the Fv region of monoclonal antibody PR1 and a truncated form of Pseudomonas exotoxin.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/8421689PubMed
8419938Soluble CD4 enhances the efficacy of immunotoxins directed against gp41 of the human immunodeficiency virus.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/8419938PubMed
8234302Central oxytocin inhibition of salt appetite in rats: evidence for differential sensing of plasma sodium and osmolality.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/8234302PubMed
8190124Hormonotoxins: the role of positive charge of lysine residue on the immunological, biological and cytotoxic properties of ovine lutropin-S-S-gelonin conjugates.Mol Cell Biochem1994https://conductscience.org/library/papers/8190124PubMed
7927788Primate antibody response to immunotoxin: serological and computer-aided analysis of epitopes on a truncated form of Pseudomonas exotoxin.Infect Immun1994https://conductscience.org/library/papers/7927788PubMed
7898459Diphtheria toxin-related cytokine fusion proteins: elongation factor 2 as a target for the treatment of neoplastic disease.Mol Cell Biochem1994https://conductscience.org/library/papers/7898459PubMed
7807185Immunotoxin therapy of leptomeningeal neoplasia.J Neurooncol1994https://conductscience.org/library/papers/7807185PubMed
7734325Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.Br J Cancer1995https://conductscience.org/library/papers/7734325PubMed
7692443Eradication of large solid tumors in mice with an immunotoxin directed against tumor vasculature.Proc Natl Acad Sci U S A1993https://conductscience.org/library/papers/7692443PubMed
7683746Disulfide linked alpha oLH-gelonin conjugate failed to recombine with beta oLH subunit to generate bioeffective hormonotoxin.Mol Cell Biochem1993https://conductscience.org/library/papers/7683746PubMed
7619070Studies on crystal structures, active-centre geometry and depurinating mechanism of two ribosome-inactivating proteins.Biochem J1995https://conductscience.org/library/papers/7619070PubMed
7600567Pharmacokinetics, tissue distribution, and in vivo antitumor effects of the antimelanoma immunotoxin ZME-gelonin.Cancer Immunol Immunother1995https://conductscience.org/library/papers/7600567PubMed

See all 49 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/3317828

GET https://conductscience.org/api/papers/v1/3317828/cited_by?page=2